
15-Year Long Stagnant Life Expectancy Trend In U.S. Continues
Approximately 525,000 more deaths occurred in the United States in 2023 than would have been expected based on pre-2010 mortality trends. The large number of excess deaths can be attributed to many different diseases and conditions. Cardiovascular disease continues to top the causes of mortality, along with cancer. But medical errors, overdose fatalities, gun deaths, infant mortality and other causes all contribute to the troublesome trend. U.S. life expectancy has been largely stagnant for 15 years.
The Centers for Disease Control and Prevention report on mortality in the U.S. shows that life expectancy at birth rose from 77.5 in 2022 to 78.4 in 2023. While the bump between 2022 and 2023 is good news and signals a continued bounce-back from significant declines in 2020 and 2021 owing to the COVID-19 pandemic, the figure is still below the 2010 level. And preliminary data suggest that compared to 2023 the improvement in life expectancy in 2024 could be much smaller, as the rebound appears to be losing steam.
Over the next 25 years, life expectancy in the U.S. is projected to rise by approximately two years—far less than in other wealthy, industrialized nations, according to a study published in The Lancet and carried out by the Institute for Health Metrics and Evaluation. Specifically, U.S. life expectancy is forecast to increase from its 2023 level to 80·4 years in 2050. This modest gain will see the U.S. fall from 49th to 66th globally in life expectancy rankings.
Life expectancy is an estimate of the average number of years a baby born in a given year might expect to live, given death rates at that time. It's considered a fundamental measure of a population's health.
A newly released report by the Bloomberg American Health Initiative highlights some of the reasons why the sharp divergence between U.S. life expectancy and its peers will likely persist, including the relatively elevated incidence and prevalence of cardiovascular disease, obesity and diabetes, as well as high levels of drug overdoses, gun deaths, motor vehicle fatalities and infant and maternal mortality. These help to explain, for example, the 2.7-year gap in life expectancy between the U.S. and the United Kingdom.
Other rich countries such as Japan, Korea, Portugal, the U.K. and Italy all currently enjoy a life expectancy of 80 years or more. And since 1980 the gap between the U.S. and its peers has widened substantially.
A Journal of the American Medical Association study analyzing 170 health indicators for U.S. children from 2007–2023 paints an especially sobering picture for the nation's youth, as infant mortality is 1.8 times higher than other wealthy nations; firearms are a top cause of death; obesity, anxiety and depression are rising relative to peers.
What has alarmed policymakers for decades is that the U.S. experiences comparatively subpar life expectancy despite spending considerably more on healthcare. In fact, the U.S. spends much more in absolute and per capita terms on healthcare than any other nation.
Health and Human Services Secretary Robert F. Kennedy Jr. has spoken of a 'life expectancy crisis.' He points to chronic diseases as the main underlying problem. Specifically, he cites rising rates of obesity, diabetes and cancer, as well as autoimmune diseases, neurodevelopmental disorders, Alzheimer's, asthma and addiction.
Kennedy blames poor diets and environmental toxins for the increase in chronic disease rates. It follows that he's focused on chronic disease prevention, with a special emphasis on nutrition and removing certain ingredients and additives from food and beverages. Diet has invariably been integral to the Make America Healthy Again movement that Kennedy began.
MAHA is taking aim at artificial dyes, pesticides, and additives, while trying to shift American eating habits away from ultra-processed foods. Kennedy is planning a public awareness campaign on the links between ultra-processed food and diabetes.
While Kennedy's ideas to improve nutrition have some backing in the public health community, they could clash with the vested interests of the food industry as well as other Trump administration policies.
Kennedy and his allies say Europe's food regulations help explain its lower rates of chronic disease, but experts suggest they may be overlooking European policies with possibly more impact, such as universal access to healthcare, a lower poverty rate and less exposure to air pollution. Additionally, Kennedy may be ignoring certain areas which could ameliorate the stagnant life expectancy trend, such as policies targeting gun violence, infant and maternal mortality, motor vehicle fatalities and medical errors.
Equally important are courses of action that would tackle 'diseases of despair,' such as suicide, alcoholism and illicit drug use. Kennedy says he's determined to 'prevent addiction,' but steep budget cuts passed by Congress may undermine his efforts at curbing substance abuse disorders.
Public health in America faces enormous challenges, not least of which are shrinking budgets at the federal and state levels. Experts across the political divide agree that addressing stagnant life expectancy requires sustained government funding of a wide range of initiatives that affect public health.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
8 minutes ago
- Yahoo
Hims & Hers Health (NYSE:HIMS) Misses Q2 Revenue Estimates, Stock Drops 12%
Telehealth company Hims & Hers Health (NYSE:HIMS) fell short of the market's revenue expectations in Q2 CY2025, but sales rose 72.6% year on year to $544.8 million. On the other hand, the company expects next quarter's revenue to be around $580 million, close to analysts' estimates. Its GAAP profit of $0.17 per share was 13% above analysts' consensus estimates. Is now the time to buy Hims & Hers Health? Find out in our full research report. Hims & Hers Health (HIMS) Q2 CY2025 Highlights: Revenue: $544.8 million vs analyst estimates of $550.8 million (72.6% year-on-year growth, 1.1% miss) EPS (GAAP): $0.17 vs analyst estimates of $0.15 (13% beat) Adjusted EBITDA: $82.24 million vs analyst estimates of $72.2 million (15.1% margin, 13.9% beat) The company reconfirmed its revenue guidance for the full year of $2.35 billion at the midpoint EBITDA guidance for the full year is $315 million at the midpoint, below analyst estimates of $319.4 million Operating Margin: 4.9%, up from 3.5% in the same quarter last year Free Cash Flow was -$69.43 million, down from $47.57 million in the same quarter last year Customers: 2.44 million, up from 2.37 million in the previous quarter Market Capitalization: $14 billion 'It's never been more clear that we are delivering exactly what millions of people have been waiting for: access to personalized, high-quality care that meets people where they are. From the momentum of our business to the results our customers are achieving, we are more confident than ever that our model is helping people optimize their health and realize the benefits of precision medicine,' said Andrew Dudum, co-founder and CEO. Company Overview Originally launched with a focus on stigmatized conditions like hair loss and sexual health, Hims & Hers Health (NYSE:HIMS) operates a consumer-focused telehealth platform that connects patients with healthcare providers for prescriptions and wellness products. Revenue Growth Examining a company's long-term performance can provide clues about its quality. Any business can experience short-term success, but top-performing ones enjoy sustained growth for years. Over the last five years, Hims & Hers Health grew its sales at an incredible 78.1% compounded annual growth rate. Its growth surpassed the average healthcare company and shows its offerings resonate with customers, a great starting point for our analysis. Long-term growth is the most important, but within healthcare, a half-decade historical view may miss new innovations or demand cycles. Hims & Hers Health's annualized revenue growth of 68.3% over the last two years is below its five-year trend, but we still think the results suggest healthy demand. We can better understand the company's revenue dynamics by analyzing its number of customers, which reached 2.44 million in the latest quarter. Over the last two years, Hims & Hers Health's customer base averaged 43.3% year-on-year growth. Because this number is lower than its revenue growth, we can see the average customer spent more money each year on the company's products and services. This quarter, Hims & Hers Health achieved a magnificent 72.6% year-on-year revenue growth rate, but its $544.8 million of revenue fell short of Wall Street's lofty estimates. Company management is currently guiding for a 44.4% year-on-year increase in sales next quarter. Looking further ahead, sell-side analysts expect revenue to grow 28.5% over the next 12 months, a deceleration versus the last two years. Still, this projection is healthy and indicates the market sees success for its products and services. Today's young investors likely haven't read the timeless lessons in Gorilla Game: Picking Winners In High Technology because it was written more than 20 years ago when Microsoft and Apple were first establishing their supremacy. But if we apply the same principles, then enterprise software stocks leveraging their own generative AI capabilities may well be the Gorillas of the future. So, in that spirit, we are excited to present our Special Free Report on a profitable, fast-growing enterprise software stock that is already riding the automation wave and looking to catch the generative AI next. Operating Margin Although Hims & Hers Health was profitable this quarter from an operational perspective, it's generally struggled over a longer time period. Its expensive cost structure has contributed to an average operating margin of negative 1.7% over the last five years. Unprofitable healthcare companies require extra attention because they could get caught swimming naked when the tide goes out. On the plus side, Hims & Hers Health's operating margin rose by 43.9 percentage points over the last five years, as its sales growth gave it operating leverage. Zooming in on its more recent performance, we can see the company's trajectory is intact as its margin has also increased by 13.6 percentage points on a two-year basis. These data points are very encouraging and show momentum is on its side. In Q2, Hims & Hers Health generated an operating margin profit margin of 4.9%, up 1.4 percentage points year on year. This increase was a welcome development and shows it was more efficient. Earnings Per Share Revenue trends explain a company's historical growth, but the long-term change in earnings per share (EPS) points to the profitability of that growth – for example, a company could inflate its sales through excessive spending on advertising and promotions. Hims & Hers Health's full-year EPS flipped from negative to positive over the last five years. This is a good sign and shows it's at an inflection point. In Q2, Hims & Hers Health reported EPS at $0.17, up from $0.06 in the same quarter last year. This print easily cleared analysts' estimates, and shareholders should be content with the results. Over the next 12 months, Wall Street expects Hims & Hers Health's full-year EPS of $0.80 to grow 4.4%. Key Takeaways from Hims & Hers Health's Q2 Results We enjoyed seeing Hims & Hers Health beat analysts' EPS expectations this quarter. We were also happy its customer base narrowly outperformed Wall Street's estimates. On the other hand, its EBITDA guidance for next quarter missed and its revenue fell slightly short of Wall Street's estimates. Overall, this quarter could have been better. The stock traded down 12% to $55.84 immediately after reporting. Should you buy the stock or not? We think that the latest quarter is just one piece of the longer-term business quality puzzle. Quality, when combined with valuation, can help determine if the stock is a buy. We cover that in our actionable full research report which you can read here, it's free.
Yahoo
8 minutes ago
- Yahoo
NYC air quality worsens again amid Canadian wildfire haze
NEW YORK — Hazy skies and low air quality returned to the five boroughs on Monday, as smoke from Canadian wildfires again created a gray scene in the New York skies. All of New York state and almost all of New England was under an air quality alert from the National Weather Service on Monday afternoon. The warning for New York City extended until midnight. 'Air quality is unhealthy for sensitive groups, including older adults, children, and people with heart or lung conditions,' NYC's emergency department wrote on social media. 'You may notice a faint smell of smoke, and low visibility conditions.' It has become a depressingly familiar story for New Yorkers in recent years. Smoke from uncontrolled wildfires in Canada, most of them in the province of Manitoba, has been carried south and east by common wind patterns. The worst air quality in recent years occurred in June 2023, when the smoke became so thick it created an orange haze over the city. However, the subpar air quality has returned to the city in each of the past two summers as well, including multiple times earlier this year. 'Limit outdoor activity, close windows, use air purifiers if available, and consider wearing a high-quality mask if you must go outside and are in a sensitive group,' NYC Emergency Management warned. New York was hardly alone in dealing with poor air quality on Monday. All of Maine, New Hampshire, Massachusetts, Rhode Island, Connecticut and Delaware, along with the majority of Vermont were also under air quality alerts. _____


CNN
10 minutes ago
- CNN
Video: Passengers rush to evacuate smoke-filled train
Video shows passengers rushing to evacuate a smoke-filled PATH train in New Jersey. Thirteen people were treated for smoke inhalation and 9 were transported to the hospital, according to the Port Authority of New York and New Jersey.